Journal article
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
- Abstract:
-
Objective To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi).
Methods Adults with active PsA (≥3 swollen and ≥3 tender joints) who discontinued ≤2 TNFi due to IR (lack of efficacy or intolerance) were randomised (2:1) to subcutaneous guselkumab 100 mg or placebo at week 0, week 4, then e...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, 2.4MB, Terms of use)
-
- Publisher copy:
- 10.1136/annrheumdis-2021-220991
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Volume:
- 81
- Issue:
- 3
- Pages:
- 359-369
- Publication date:
- 2021-11-24
- Acceptance date:
- 2021-10-20
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1205634
- Local pid:
-
pubs:1205634
- Deposit date:
-
2021-10-22
Terms of use
- Copyright holder:
- Coates et al.
- Copyright date:
- 2021
- Rights statement:
- This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record